| Nov 11 |
Unicycive NDA for hyperphosphatemia asset accepted by FDA
|
| Nov 11 |
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
|
| Oct 28 |
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
|
| Oct 16 |
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024
|
| Oct 16 |
Results of Phase I trial shed positive light on UNI-494 for acute kidney injury
|
| Oct 9 |
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers
|
| Sep 20 |
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
|
| Sep 16 |
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
|
| Sep 16 |
Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024
|
| Sep 5 |
Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
